Acute renal failure under dasatinib therapy

Renal Failure

Volumn 32, Issue 1, 2010, Pages 147-149

  Ozkurt, Sultan ^a   Temiz, Gokhan ^a   Acikalin, Mustafa Fuat ^a   Soydan, Mehmet ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Acute renal failure; Chronic myeloid leukemia; Dasatinib; Tyrosine kinase inhibitors

Indexed keywords

DASATINIB; NILOTINIB;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROENTERITIS; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LABORATORY TEST; PRIORITY JOURNAL;

EID: 76449116744     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860220903391226     Document Type: Article

References (12)

1. Holstein SA, Stokes JB, Hohl RJ. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res. 2009;33:334-347.
2. Wong SF. New dosing schedules of dasatinib for CML and adverse event management. J Hematol Oncol. 2009;2:10.
3. Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE. Dasatinib treatment for Philadelphia chromosome-positive leukemias. Cancer. 2009;115:1381-1394.
4. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN 107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129-141.
5. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500-4505.
6. Steinberg M. Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther. 2007;29:2289-2308.
7. Kitiyakara C, Atichartakarn V. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant. 2002;17:685-687.
8. Pou M, Saval N, Vera M, et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 2003;44:1239-1241.
9. Foringer JR, Verani RR, Tjia VM, Finkel KW, Samuels JA, Guntupalli JS. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother. 2005;39;2136-2138.
10. François H, Coppo P, Hayman JP, Fouqueray B, Ronco P. Partial Fanconi syndrome induced by imatinib therapy: A novel cause of urinary phosphate loss. Am J Kidney Dis. 2008;51:298-301.
11. Christopher LJ, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008;36:1357-1364.
12. Sonmez M, Cobanoglu U, Ovali E, Omay B. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance to imatinib and renal failure. J Clin Pharm Therap. 2008;33:329-330